VTGN vs. ANVS, AMLX, KPTI, SGMT, RPTX, SYRS, CTXR, EBS, GLYC, and RLMD
Should you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Annovis Bio (ANVS), Amylyx Pharmaceuticals (AMLX), Karyopharm Therapeutics (KPTI), Sagimet Biosciences (SGMT), Repare Therapeutics (RPTX), Syros Pharmaceuticals (SYRS), Citius Pharmaceuticals (CTXR), Emergent BioSolutions (EBS), GlycoMimetics (GLYC), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical preparations" industry.
Annovis Bio (NYSE:ANVS) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations.
Annovis Bio has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Annovis Bio has a net margin of 0.00% compared to Annovis Bio's net margin of -3,073.51%. Annovis Bio's return on equity of -72.10% beat Vistagen Therapeutics' return on equity.
Annovis Bio has higher earnings, but lower revenue than Vistagen Therapeutics.
Annovis Bio presently has a consensus target price of $25.25, indicating a potential upside of 375.52%. Vistagen Therapeutics has a consensus target price of $19.00, indicating a potential upside of 332.80%. Given Vistagen Therapeutics' higher probable upside, equities research analysts plainly believe Annovis Bio is more favorable than Vistagen Therapeutics.
In the previous week, Annovis Bio had 34 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 35 mentions for Annovis Bio and 1 mentions for Vistagen Therapeutics. Annovis Bio's average media sentiment score of 0.44 beat Vistagen Therapeutics' score of 0.06 indicating that Vistagen Therapeutics is being referred to more favorably in the news media.
15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are owned by institutional investors. 38.3% of Annovis Bio shares are owned by company insiders. Comparatively, 1.0% of Vistagen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Vistagen Therapeutics received 263 more outperform votes than Annovis Bio when rated by MarketBeat users. However, 94.74% of users gave Annovis Bio an outperform vote while only 72.24% of users gave Vistagen Therapeutics an outperform vote.
Summary
Vistagen Therapeutics beats Annovis Bio on 8 of the 15 factors compared between the two stocks.
Get Vistagen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vistagen Therapeutics Competitors List
Related Companies and Tools
